ClinicalTrials.gg
CompletedNCT00673842REFINE-ICDUpdated May 30, 2025

Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

A Phase 3 interventional study of Implantable Cardioverter Defibrillator + Usual Care and Usual care in Myocardial Infarction and Sudden Death, sponsored by University of Calgary. Completed at 79 sites in 15 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-30.

Sponsored by University of Calgary · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
700
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study will assess whether an implantable defibrillator will increase the likelihood of survival in patients who have had a heart attack, have abnormal test results from a 24 hour heart monitor, and who have low normal heart function.

Read the detailed description

The REFINE ICD trial will assess whether prophylactic ICD therapy, guided by non-invasive risk assessment tools, reduces mortality in MI survivors with better-preserved LV function.

02

Conditions studied

  • Myocardial Infarction
  • Sudden Death

Keywords

  • Noninvasive assessment
  • Holter
03

In context

Myocardial Infarction

2,270 studies on the registry are indexed under Myocardial Infarction; 371 are open to participants now.

This study's planned enrollment of 700 is above the median of 150 across 1,314 interventional studies indexed under Myocardial Infarction.

Browse Myocardial Infarction studies →

Lead sponsor

University of Calgary is the lead sponsor of 703 studies on the registry; 196 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 2 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Site investigators are responsible for screening. Subjects must meet all inclusion criteria. Subjects with any exclusion criteria will be excluded.

Initial inclusion criteria (eligibility for Holter screening).

  • 18 - 80 years old at time of consent
  • History of MI ≥ 2 months prior to screening based on ESC/ACCF/AHA/WHF criteria (both STEMI and NSTEMI subjects are eligible)
  • Appropriate post-MI management including revascularization where indicated
  • No for transvenous ICD placement (e.g., mechanical tricuspid valve, known vascular access problems, active sepsis, etc.)
  • 36% - 50% measured at least 40 days after a confirmed MI ≥ 3 months after coronary angioplasty or coronary bypass surgery and within the following time windows:

    • LVEF ≤ 7 months of screening visit if index MI was ≤ 1 year of enrolment
    • LVEF ≤ 13 months of screening visit if index MI was > 1 \& \< 3 years of enrolment
    • LVEF ≤ 25 months of screening visit if index MI was ≥ 3 years of enrolment
  • Proven, necessary or appropriate medications (e.g. beta-blocker, ACE inhibitor / ARB, statin, and anti-)
  • In normal sinus rhythm ( documented) ≤ 8 weeks prior to the screening Holter
  • Written
  • Able and willing to complete the screening Holter, including the six-minute hall walk

Additional inclusion criterion (eligibility for randomization).

  • Abnormal HRT \& TWA (core lab interpretation) on Holter performed at least 2 months after the index MI and the specified time after coronary revascularization
  • In normal sinus rhythm (ECG documented) within 8 weeks prior to the screening Holter
  • In normal sinus rhythm for ≥ 18 hours of the 24 hr screening Holter as determined by the study Holter Core Lab

Exclusion criteria (randomization or registry).

  • Use of antiarrhythmic drugs
  • Clinical indication for permanent pacemaker or a cardiac resynchronization device
  • Clinical indication for an ICD or cardiac resynchronization ICD
  • Prior implantation of a pacemaker, ICD, or Cardiac Resynchronization device
  • Any condition, in the investigator's judgment, that would limit to \< 12 months
  • Chronic renal failure (hemodialysis or peritoneal dialysis)
  • Active ischemia that is amenable to revascularization if not previously revascularized
  • Participation in another trial that may interfere with the REFINE ICD results.
  • Pregnancy
  • Inability to comply with the follow-up schedule
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
700 participants (estimated)

Study arms

  • Experimental
    ICD + Usual Care

    Implantable Cardioverter Defibrillator + Usual Care

    Device: Implantable Cardioverter Defibrillator + Usual Care

  • Active comparator
    Usual Care

    Usual post-MI care

    Other: Usual care

Interventions

  • DeviceImplantable Cardioverter Defibrillator + Usual Care

    Any Medtronic approved single chamber or dual chamber implantable cardioverter defibrillator (ICD)

    Also known as: Implantable Cardioverter Defibrillator, ICD

  • OtherUsual care

    Usual post-MI care

    Also known as: Standard medical therapy alone

06

What researchers measure

Primary outcomes

  1. Mortality

    Time frame: Minimum of 18 months of follow-up (average follow-up of 5 years).

Secondary outcomes

  1. Cardiac death

    Time frame: Average follow-up 5 years.

  2. Arrhythmic death

    Time frame: Average follow-up 5 years.

  3. Arrhythmic syncope

    Time frame: Average follow-up 5 years.

  4. Appropriate ICD therapies

    Time frame: Average follow-up 5 years.

  5. Quality of life

    Time frame: Average follow-up 5 years.

  6. Inappropriate ICD therapies

    Time frame: Five years (average)

07

Study locations

79 sites
  • Heart Center Research LLC
    Huntsville, Alabama 35801, United States
  • Colorado Heart and Vascular
    Lakewood, Colorado 80228, United States
  • James A Haley Veterans' Center
    Tampa, Florida 33612, United States
  • The Heart Group/Deaconess
    Evansville, Indiana 47630, United States
  • Iowa Heart Center
    West Des Moines, Iowa 50266, United States
  • Delmarva Heart Foundation
    Salisbury, Maryland 21804, United States
  • Beth Israel Deaconess
    Boston, Massachusetts 02215, United States
  • Washington University Medical School
    Saint Louis, Michigan 63110, United States
  • St. John Providence Hospital
    Southfield, Michigan 48075, United States
  • Lester E Cox Medical Center
    Springfield, Missouri 65807, United States
  • The Valley Hospital
    Ridgewood, New Jersey 07450, United States
  • Associated Cardiovascular Consultants/Lourdes Cardiology Services
    Voorhees, New Jersey 08034, United States
  • North Shore LIJ
    New York, New York 10029, United States
  • New York Presbyterian Hospital
    New York, New York 10032, United States
  • Northeast Ohio Cardiovascular Specialists
    Akron, Ohio 44304, United States
  • The Lindner Research Center
    Cincinnati, Ohio 45219, United States
  • Bethesda North Hospital
    Cincinnati, Ohio 45242, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Doylestown Cardiology
    Doylestown, Pennsylvania 18901, United States
  • University of Pittsburgh Medical Center UPMC Presbyterian
    Pittsburgh, Pennsylvania 15213, United States
  • Geisinger Wyoming Valley Medical Center
    Wilkes-Barre, Pennsylvania 18722, United States
  • Greenville Hospital System
    Greenville, South Carolina 29605, United States
  • St. Thomas Research Institute
    Nashville, Tennessee 37203, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Amarillo Heart Group
    Amarillo, Texas 79106, United States
  • University of Virginia
    Charlottesville, Virginia 22908, United States
  • Centra Medical Group
    Lynchburg, Virginia 24510, United States
  • Heart Clinics Northwest
    Spokane, Washington 99204, United States
  • UZ Leuven - Campus Gasthuisberg
    Leuven, Belgium
  • Libin Cardiovascular Institute of Alberta
    Calgary, Alberta T2N 4Z6, Canada
  • Royal Alexandra Hospital
    Edmonton, Alberta T5H 3V9, Canada
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • Fraser Clinical Trials
    New Westminster, British Columbia V3L 3W4, Canada
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • St. Paul's Hospital/Providence Health Care
    Vancouver, British Columbia V6E 1M7, Canada
  • Victoria Cardiac Arrhythmia Trials
    Victoria, British Columbia V8Z 0B9, Canada
  • St. Boniface Hospital
    Winnipeg, Manitoba R2H 2A6, Canada
  • Cardio 1
    Winnipeg, Manitoba R3L 1Z5, Canada
  • New Brunswick Heart Centre
    St. John, New Brunswick E2L 2L4, Canada
  • Queen Elizabeth II Health Sciences Center
    Halifax, Nova Scotia B3H 3A7, Canada
  • Cambridge Cardiac Care Centre
    Cambridge, Ontario N1R 6V6, Canada
  • Hamilton Health Sciences Centre
    Hamilton, Ontario L8L 2X2, Canada
  • University of Western Ontario
    London, Ontario N0L 1W0, Canada
  • Southlake
    Newmarket, Ontario L3Y 2P9, Canada
  • Ottawa Heart Institute
    Ottawa, Ontario K1Y 4W7, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3N5, Canada
  • St. Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Montreal Heart Institute
    Montreal, Quebec H1T 1C8, Canada
  • CHUM
    Montreal, Quebec H2W 1T8, Canada
  • McGill University Health Centre
    Montreal, Quebec H3G 1A4, Canada
  • Centre Hospitalier Universitaire de Sherbrooke (CHUS)
    Sherbrooke, Quebec J1H 5N4, Canada
  • Centre Hospitalier Universitaire Regional de Trois-Rivieres (CHRTR)
    Trois-Rivieres, Quebec G8Z 3R9, Canada
  • Prairie Vascular Research Network
    Regina, Saskatchewan S4P 0W5, Canada
  • Royal University Hospital
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Quebec Heart Institute
    Laval, G1V 4G5, Canada
  • HUCH Helsinki University Central Hospital
    Helsinki, Finland
  • University of Oulu
    Oulu, Finland
  • CHRU Brest - Hôpital de la Cavale Blanche
    Brest, France
  • Hôpital Guillaume et René Laënnec - CHU de Nantes
    Nantes, France
  • Clinique Pasteur
    Toulouse, France
  • Universitätsmedizin Göttingen Georg-August-Universität
    Göttingen, 37099, Germany
  • Zala Megyei Kórház
    Zalaegerszeg, Hungary
  • Azienda Ospedaliera Papa Giovanni XXIII
    Bergamo, Italy
  • Policlinico Sant' Orsola - Malpighi
    Bologna, Italy
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, Italy
  • Oslo Universitetssykehus Rikshospitalet
    Oslo, Norway
  • King Saud University
    Riyadh, Saudi Arabia
  • Slovak Medical University in Bratislava
    Bratislava, Slovakia
  • Unitas Hospital
    Centurion, South Africa
  • Hospital General Universitario de Alicante (HGUA)
    Alicante, 03010, Spain
  • Hospital Universitario Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
  • Hospital Universitario La Paz
    Madrid, Spain
  • Universitetssjukhuset Örebro
    Örebro, 70185, Sweden
  • Liverpool Heart and Chest Hospital
    Liverpool, United Kingdom
  • Great Western Hospital NHS Trust
    Swindon, United Kingdom
08

References and documents

Publications

  • Perkiomaki J, Exner DV, Piira OP, Kavanagh K, Lepojarvi S, Talajic M, Karvonen J, Philippon F, Junttila J, Coutu B, Huikuri H. Heart Rate Turbulence and T-Wave Alternans in Patients with Coronary Artery Disease: The Influence of Diabetes. Ann Noninvasive Electrocardiol. 2015 Sep;20(5):481-7. doi: 10.1111/anec.12244. Epub 2015 Jan 15. PubMed 25589197 ↗

Related links

Individual participant data

Plan to share: Undecided — uncertain

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2011 to primary completion in Oct 2024, 162 months.

Of 33 non-industry phase 3 interventional studies under Myocardial Infarction, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 73. This study's 162 months is above that.

Counting every sponsor, half of 57 studies reached it within 43 months; a quarter within 30 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2008
First posted
May 7, 2008
StartActual
Apr 18, 2011
Primary completionActual
Oct 31, 2024
CompletionActual
Oct 31, 2024
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00673842
Collaborators
Canadian Institutes of Health Research (CIHR), Alberta Innovation and Science, Medtronic, GE Healthcare, Cardiac Arrhythmia Network of Canada, Accelerating Clinical Trials Consortium
Responsible party
Dr. Derek Exner (Professor and Canada Research Chair in Cardiovascular Clinical Trials, University of Calgary) — Principal investigator
First posted
May 7, 2008
Start date
Apr 18, 2011
Primary completion
Oct 31, 2024
Completion
Oct 31, 2024
Last update
May 30, 2025

Study contacts

Derek V Exner, MD, MPH
principal investigator · University of Calgary

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion